Vitamin D to Ivermectin — A 2026 Cancer Prevention Framework
Quick Answer: The ROOT Protocol is a tiered, nutraceutical-based cancer-prevention framework developed by Dr. Paul Marik and Dr. Justus Hope. It begins with a three-agent foundation — green tea EGCG, curcumin, and vitamin D3 — and adds omega-3s, berberine, and sulforaphane in higher tiers. The top tier, Root 9, adds the prescription drugs celecoxib, ivermectin, and mebendazole, and is scoped by its own authors to people with hereditary cancer syndromes under specialist supervision, not general use. It is best understood as a supplement escalation ladder layered on top of the diet and lifestyle foundation described in OneDayMD's I-PREVENT Cancer Protocol.
Medically reviewed and updated by the OneDayMD Editorial Team | Last updated July 11, 2026
Table of Contents
- 1. Why Cancer Prevention Needs a Systems-Level Rethink
- 2. The Metabolic Drivers Screening Doesn't Address
- 3. The ROOT Protocol: From 3 Agents to 9
- 4. Root 3 and Root 4: The Foundational Tier
- 5. Root 5 and Root 6: Berberine and Sulforaphane
- 6. Root 9: For Hereditary Cancer Risk Only
- 7. The ROOT+ Variants: Aged Garlic Extract
- 8. Dosing and Safety Profile
- 9. The 2026 Evidence Debate: ASCO vs. the Repurposed-Drug Camp
- 10. How ROOT Fits Into the I-PREVENT Framework
- 11. Key Takeaways
- 12. Frequently Asked Questions
- 13. Medical Disclaimer & Disclosures
Source note: This article synthesizes and comments on three publications: OneDayMD's own I-PREVENT Cancer Protocol, and two 2026 essays by Dr. Paul Marik, MD (with Dr. Justus Hope, MD, on the second) — "What the Public Is Not Told About Cancer Prevention" and "Preventing Cancer: The ROOT Protocols." The ROOT Protocol name, tier structure, and germline-risk framework originate with Drs. Marik and Hope; we credit that work throughout rather than presenting it as our own. OneDayMD has no financial relationship with Dr. Marik, the Independent Medical Alliance (IMA), or their publications.
1. Why Cancer Prevention Needs a Systems-Level Rethink
The default cancer narrative most people absorb from pharmaceutical advertising, public health campaigns, and academic medicine goes something like this: cancer is mostly genetic, mostly bad luck, and best addressed through early detection and ever-better drugs. That narrative isn't wrong, but it is incomplete, and the gap matters.
The American Cancer Society projected 2,001,140 new cancer cases and 611,720 cancer deaths in the United States for 2024 alone. A 2024 analysis in The Lancet Public Health found that 17 cancer types are becoming more common in younger generations, with rising mortality alongside that trend — colorectal cancer among them, now the leading cause of cancer death in men under 50 and the second leading cause in women under 50, having ranked fourth as recently as the late 1990s.
That shift has tracked almost exactly with the rise of obesity, type 2 diabetes, insulin resistance, metabolic syndrome, sedentary living, and ultra-processed food consumption. As Dr. Paul Marik has argued, this parallel is unlikely to be a coincidence — and it points toward a version of cancer prevention that looks past genetics alone toward the metabolic and inflammatory "terrain" in which cancer either does or doesn't take hold.
2. The Metabolic Drivers Screening Doesn't Address
Mammograms, colonoscopies, PSA tests, and CT scans are valuable tools, but they detect disease that has already begun — they don't explain why it started. Marik's core argument is that mainstream prevention messaging over-indexes on screening and pharmaceuticals while underemphasizing several biologically plausible, modifiable drivers:
| Driver | Why it matters |
|---|---|
| Obesity & hyperinsulinemia | Adipose tissue behaves as an active endocrine and inflammatory organ, driving insulin resistance, elevated IGF-1, and chronic low-grade inflammation — all plausible tumor-promoting signals. |
| The Warburg effect | Many tumors are unusually glucose-dependent, relying on glycolysis even when oxygen is available. This doesn't mean sugar "feeds" cancer overnight, but chronic hyperglycemia and hyperinsulinemia likely favor a permissive environment. |
| Ultra-processed foods | Linked to inflammation, gut dysbiosis, and insulin resistance. See OneDayMD's dedicated review of ultra-processed food and cancer risk. |
| Sarcopenia & inactivity | Muscle tissue regulates glucose metabolism and inflammation. Loss of muscle mass through sedentary living compounds insulin resistance. |
| Circadian disruption | IARC/WHO classifies shift work involving circadian disruption as "probably carcinogenic to humans" (Group 2A), via effects on melatonin, immune regulation, and metabolism. |
| Environmental exposures | Pesticides, microplastics, endocrine disruptors, and air pollution add oxidative stress and hormonal disruption on top of dietary and metabolic risk. |
None of this means cancer is fully preventable, or that a patient's disease is somehow "their fault." Cancer is genuinely multifactorial. But it does mean prevention is more actionable than a purely genetic framing suggests — which is exactly the premise behind the ROOT Protocol.
3. The ROOT Protocol: From 3 Agents to 9
Drs. Marik and Hope built the ROOT Protocol as a stepwise, AI-assisted framework (developed with Perplexity) that adds one evidence-ranked agent at a time, starting from a three-agent baseline. Each tier's name reflects its total agent count — Root 3, Root 4, Root 5, Root 6, and finally Root 9 once three prescription drugs are added on top.
Everyone from young adults to centenarians is, in Marik and Hope's framing, a reasonable candidate for the Root 3 foundation. Root 4 is positioned as the basic protocol for older adults, since most cancers occur after age 65 due to cumulative risk exposure. Root 5 and Root 6 are for those at elevated but non-hereditary risk. Root 9 is reserved for a narrower group discussed in Section 6.
4. Root 3 and Root 4: The Foundational Tier
Green tea EGCG. Epigallocatechin gallate is the best-studied catechin in green tea. Preclinical work shows it can suppress glucose uptake in cancer cells by blocking GLUT1 and hexokinase 2, disrupt the Warburg effect, push pro-inflammatory "M2" tumor-associated macrophages toward an antitumor "M1" phenotype, and turn immunologically "cold" tumors "hot" by reducing regulatory T cells and myeloid-derived suppressor cells. OneDayMD's own review of the Minnesota Green Tea Trial covers the clinical breast-density data in more depth.
Curcumin. Turmeric's active polyphenol inhibits AKT/mTOR and Wnt/β-catenin signaling, reduces NF-κB-driven inflammatory cytokines, and induces apoptosis across a wide range of cancer cell lines. As covered in the I-PREVENT protocol, raw turmeric is a poor delivery vehicle — only about 3% curcumin by weight, with roughly 1% bioavailability — so a bioavailable extract taken with fat or piperine is standard practice.
Vitamin D3. Vitamin D affects nearly every stage of carcinogenesis: it stabilizes IκBα to blunt NF-κB inflammatory signaling, activates the Nrf2 antioxidant pathway, upregulates DNA-repair genes including TP53, BRCA1, and ATM, and inhibits VEGF-driven angiogenesis. The 2022 DO-HEALTH trial — a 3-year, 2×2×2 factorial RCT combining vitamin D3 (2,000 IU/day), marine omega-3 (1 g/day), and a simple home strength program — found an adjusted hazard ratio of 0.39 for invasive cancer in the combined-intervention group, a synergy larger than any single arm produced alone. The NIH-funded VITAL trial, though reported as an overall negative study, still found lower cancer mortality with vitamin D3 versus placebo (HR 0.72, 95% CI 0.52–1.00). There's no single universal target blood level, but most of the stronger epidemiologic data point to benefit starting around 30–40 ng/mL, with a pragmatic target of 40–60 ng/mL for prevention purposes — consistent with the range OneDayMD has recommended in the I-PREVENT protocol.
Root 4: adding omega-3. EPA and DHA compete with pro-inflammatory omega-6 fats, activate PPARs to dampen NF-κB signaling, and can trigger ferroptosis (iron-dependent lipid peroxidation) in acidic tumor microenvironments. The same DO-HEALTH data underpins this tier; a reasonable ceiling is roughly 1 gram of combined EPA/DHA per day from a low-oxidation ("low TOTOX") supplement, since both compounds are polyunsaturated and prone to oxidative damage at high doses.
5. Root 5 and Root 6: Berberine and Sulforaphane
Root 5: berberine. This plant alkaloid activates AMPK in a metformin-like fashion, upregulates pro-apoptotic BAX while suppressing BCL2, and disrupts angiogenesis via VEGF and MMP inhibition. A 6-year follow-up of a randomized trial published in Cell Reports Medicine (2025) found that berberine's protective effect against colorectal adenoma recurrence persisted years after treatment stopped — 34.7% recurrence versus 52.1% in the comparison group.
Root 6: sulforaphane. Found in cruciferous vegetables (and concentrated in broccoli sprout extract), sulforaphane inhibits histone deacetylases and DNA methyltransferases, reactivating silenced tumor-suppressor genes, while also triggering caspase-mediated apoptosis and suppressing cancer stem cell self-renewal through Wnt/β-catenin modulation. It's a mechanistic complement to the cruciferous-vegetable data already covered in the I-PREVENT protocol's colon cancer section.
6. Root 9: For Hereditary Cancer Risk Only
Root 9 is where the ROOT Protocol shifts from over-the-counter nutraceuticals to prescription drugs, and its authors are explicit that this tier is scoped to a specific population: people with confirmed inherited cancer syndromes, managed by a physician familiar with hereditary cancer risk — not the general population, and not a self-directed protocol.
| Syndrome | Gene | Approximate lifetime risk |
|---|---|---|
| Hereditary breast/ovarian cancer | BRCA1/BRCA2 | Up to ~70% breast cancer risk in women |
| Li-Fraumeni syndrome | TP53 | >50% risk of multiple cancers |
| Lynch syndrome | Mismatch-repair genes | 50–70% colorectal; up to 60% endometrial (women) |
| Familial adenomatous polyposis (FAP) | APC | Near 100% colorectal cancer without intervention |
Germline mutations of this kind account for roughly 5–10% of all cancers. For carriers, Root 9 layers three additional agents onto Root 6:
- Celecoxib — a COX-2 inhibitor already FDA-approved as adjunctive therapy for FAP. In trials, 400 mg twice daily produced a 28% reduction in colorectal polyps versus 5% with placebo. This is the one Root 9 component with an established, FDA-recognized dosing regimen for a hereditary-cancer indication.
- Ivermectin — an FDA-approved antiparasitic. Preclinical work suggests it can inhibit WNT-TCF signaling (relevant to FAP-associated colorectal cancer), suppress PAK1 kinase (relevant to BRCA-mutated breast cancer models), and induce mitochondrial oxidative stress in pancreatic cancer cell lines. These are laboratory and animal findings, not confirmed human prevention outcomes.
- Mebendazole — an FDA-approved anthelmintic. In the ApcMin/+ mouse model of FAP, it reduced intestinal tumor counts by 56% alone and up to 90% combined with the NSAID sulindac, partly by disrupting tubulin polymerization and HIF-driven hypoxia adaptation. A phase 2a human trial found doses up to 4 g/day tolerable in advanced gastrointestinal cancer, though disease still progressed in all participants — underscoring that mebendazole's role, if any, is likely as part of a combination regimen rather than monotherapy.
Neither ivermectin nor mebendazole has an established human dosing regimen for cancer prevention, and we are deliberately not providing one here. Dosing for these two agents needs to be individualized by a physician, and this is a point Dr. Marik himself has reinforced: in a June 2026 note on OneDayMD's own ivermectin/fenbendazole/mebendazole resource page, he specifically flagged a widely circulated high-dose ivermectin cancer protocol as "a potentially toxic dosing protocol which we do NOT recommend." That caution, coming from one of the therapy's own prominent advocates, is worth taking seriously regardless of where you land on the broader debate (covered in Section 9).
7. The ROOT+ Variants: Aged Garlic Extract
Aged Garlic Extract (AGE) — not the same as raw garlic or standard garlic supplements — is produced through a roughly 20-month aqueous-ethanol aging process that converts unstable compounds like allicin into more stable, odorless organosulfur compounds such as S-allyl cysteine. Any ROOT tier can be upgraded to its "+" variant (Root 3+, 4+, 5+, 6+, 9+) by adding AGE at 600 mg twice daily.
A randomized trial in patients with colorectal adenomas found that one year of high-dose AGE significantly reduced adenoma number and size compared with low-dose AGE. Mechanistically, AGE activates the Nrf2 antioxidant pathway, increases glutathione and phase II detoxification enzymes, and promotes apoptosis via p53, Bax, and caspase signaling in multiple cancer cell lines. It is generally well tolerated, though it can increase bleeding risk when combined with anticoagulants or antiplatelet drugs.
8. Dosing and Safety Profile (Root 4)
| Agent | Upper safety threshold | Key caution |
|---|---|---|
| EGCG (green tea extract) | Up to ~800 mg/day | Mild GI upset at higher doses; rare hepatotoxicity above 800 mg/day |
| Curcumin | Up to ~8 g/day | May interact with anticoagulants/antiplatelet drugs; take with fat or piperine |
| Vitamin D3 | Up to ~5,000 IU/day | Monitor serum calcium to avoid hypercalcemia at high, sustained intake |
| Omega-3 (EPA/DHA) | Bleeding risk rises above ~3 g/day | Use a low-TOTOX (low-oxidation) product; caution with anticoagulants |
Reported adverse events across these four agents combined were mostly mild: gastrointestinal symptoms (~15%), headache (~5%), and fatigue (~3%). As with any supplement regimen, anyone pregnant, immunocompromised, or on anticoagulant therapy should check with their physician before starting.
9. The 2026 Evidence Debate: ASCO vs. the Repurposed-Drug Camp
Any honest discussion of Root 9 has to include where organized oncology currently stands. In a Clinical Notice published in June 2026, the American Society of Clinical Oncology (ASCO) stated there is no robust, peer-reviewed clinical evidence that either ivermectin or fenbendazole is safe or effective for treating any human malignancy, and cautioned that both should stay within the regulatory safeguards of a formal clinical trial rather than being used as a cancer treatment or adjunct outside one. ASCO Chief Medical Officer Dr. Julie Gralow specifically pointed to social media and podcast-driven misinformation as a safety concern, and the notice acknowledged that legitimate human trials are still in early stages — including a phase I/II study combining ivermectin with checkpoint inhibitors in metastatic triple-negative breast cancer, and a phase II trial (ICONIC) expected to begin enrolling in July 2026.
Dr. Marik has pushed back on that framing in his own writing, arguing that demanding large randomized trials before considering low-cost, off-patent therapies sets an evidentiary bar that mainly well-funded pharmaceutical products can clear, and that carefully tracked observational cohorts — the kind of model used by programs like the Care Oncology Clinic's METRICS initiative — can still generate meaningful signal while formal trials catch up.
We think both points are worth holding onto at once. ASCO's underlying factual claim — that no large, peer-reviewed human trial currently demonstrates ivermectin or fenbendazole benefit in cancer — is accurate as of this writing, and the toxicity concern is real: unsupervised, high-dose regimens circulating online use doses well above those approved for parasitic infections. At the same time, Root 9's own framing already narrows its drug component to a specific, physician-supervised, hereditary-risk population, which is a meaningfully different (and more conservative) proposal than the general "take ivermectin for cancer" claims ASCO's notice was written to address. Readers should treat Root 9's prescription-drug component as an open scientific question to raise with an oncologist or integrative oncologist — not as a settled, self-directed regimen.
10. How ROOT Fits Into the I-PREVENT Framework
OneDayMD's own I-PREVENT Cancer Protocol covers the broader terrain that ROOT doesn't attempt to: the American Cancer Society's dietary guidelines, the evidence on ultra-processed food and added sugar, the Mediterranean and plant-forward dietary patterns, fiber intake, tobacco and alcohol avoidance, exercise (including the 2025 NEJM trial showing structured exercise outperforming standard post-surgical advice in colon cancer survivors), and a wider supplement list — vitamin C, zinc, magnesium, melatonin, probiotics, quercetin, carotenoids, nicotinamide, and beta-glucans — that sits alongside, rather than inside, the ROOT tiers.
Think of it as two layers of the same house: I-PREVENT is the foundation — diet, movement, sleep, toxin avoidance, and a broad base of well-studied supplements. ROOT is a more structured, sequential escalation ladder for a narrower set of agents, useful for readers who want a clearer sense of which supplement to prioritize first, second, and third, and where the evidence base changes character once you move from over-the-counter nutraceuticals to prescription drugs.
11. Key Takeaways
- Cancer prevention research in 2026 is increasingly framed around metabolic health, chronic inflammation, and environmental exposure — not genetics alone.
- The ROOT Protocol's foundational tier (Root 3: EGCG, curcumin, vitamin D3) has the most human trial support, anchored by the DO-HEALTH and VITAL trials.
- Root 4–6 add omega-3s, berberine, and sulforaphane, each with plausible mechanisms and growing but not definitive human data.
- Root 9 (celecoxib, ivermectin, mebendazole) is explicitly designed for people with confirmed hereditary cancer syndromes under specialist supervision — not a general-population or self-directed protocol.
- ASCO's 2026 Clinical Notice and Dr. Marik's own caution about high-dose ivermectin protocols both deserve serious weight; this is an active, unresolved evidence debate, not a settled question.
- ROOT complements, rather than replaces, the diet and lifestyle foundation described in the I-PREVENT protocol.
12. Frequently Asked Questions
What is the ROOT Protocol for cancer prevention?
A tiered nutraceutical framework from Dr. Paul Marik and Dr. Justus Hope that starts with EGCG, curcumin, and vitamin D3, and adds agents in sequence through Root 9.
Is the ROOT Protocol scientifically proven to prevent cancer?
Individual components have trial or preclinical support of varying strength; the combined regimen itself hasn't been tested as a single protocol in a large randomized trial, and Root 9's drug component remains investigational.
Who should consider Root 9?
Only people with a confirmed hereditary cancer syndrome (e.g., BRCA1/2, Lynch syndrome, FAP), working with a physician experienced in hereditary cancer risk.
What does ASCO say about ivermectin and fenbendazole?
Its June 2026 Clinical Notice states there is no robust, peer-reviewed clinical evidence supporting either drug for treating human cancer, and recommends against use outside a clinical trial.
13. Medical Disclaimer & Disclosures
Evidence grading: Throughout this article we distinguish randomized controlled trial data (DO-HEALTH, VITAL, the berberine adenoma-recurrence trial) from preclinical/mechanistic evidence (most of the ivermectin and mebendazole data) and from single observational cohorts. Preclinical and cell-line findings do not reliably predict human outcomes, and the hierarchy matters when deciding how much weight any single claim deserves.
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Nothing here should be used to start, stop, or replace any cancer treatment or screening plan. Decisions about supplements or off-label/repurposed drug use — especially celecoxib, ivermectin, and mebendazole — should be made with a qualified physician familiar with your medical history, current treatments, and, where relevant, your genetic risk profile.
Conflict of interest disclosure: OneDayMD maintains affiliate relationships with The Wellness Company (referral code ONEDAYMD) and Amazon Associates (tag df2021-20). Some product links on this site are affiliate links, meaning we may earn a commission at no additional cost to you. This did not influence the content, evidence grading, or safety cautions presented above. We have no financial relationship with Dr. Marik, Dr. Hope, or the Independent Medical Alliance.
.png)
.png)
Comments
Post a Comment